Gastric adenocarcinoma. Malignant neoplasm of stomach
Conditions
Interventions
Intervention 1: Intervention group: This group was treated with ACA1 capsules for 2100 mg per day for one month. Intervention 2: Control group: This group is treated with placebo capsules three times
Sponsors
Shahed University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with gastric adenocarcinoma whose disease has been confirmed histologically, are in the metastatic stage and at least two common chemotherapy treatments have been administered to them and the disease is not under control. Adequate bone marrow function: 40001500, Plt>100000, Hb>8 Adequate liver function: Total Bill>1.5, AST&ALT<100 Adequate kidney function: Cr<1.5 performance status=1
Exclusion criteria
Exclusion criteria: positive serology for HIV, HBV, HCV Metastasis to CNS other malignancies
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of Life. Timepoint: Start of study (before the start of the intervention) and one month after the start of ACA1 consumption. Method of measurement: EORTC-QLQ-30 Standard questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| White Blood Cell Count. Timepoint: Start studying (before starting the intervention) and one month after starting ACA1 consumption. Method of measurement: Cell Counter.;Hemoglobin. Timepoint: Start studying (before starting the intervention) and one month after starting ACA1 consumption. Method of measurement: Cell Counter.;Platelet Count. Timepoint: Start studying (before starting the intervention) and one month after starting ACA1 consumption. Method of measurement: Cell Counter.;Body Mass Index. Timepoint: Start studying (before starting the intervention) and one month after starting ACA1 consumption. Method of measurement: Meter and scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Sharifan
Shahed University
Outcome results
None listed